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ABSTRACT. In this study conformation analysis of seven drugs commonly used in the treatment of COVID-19 
was performed. The most stable conformers of the drug molecules were used as initial data for docking analysis. 
Using the Cavityplus program, the probable most active binding sites of both apo and holo forms of COVID-19 
main protease enzyme (Mpro) and spike glycoprotein of SARSCoV-2 receptors were determined. The interaction 
mechanisms of the 7 FDA approved drugs (arbidol, colchicine, dexamethasone, favipiravir, galidesivir, 
hydroxychloroquine, remdesivir) were examined using the AutoDock Vina program. The six of the seven drugs 
were found to be more stable in binding to apo form of COVID-19 Mpro and spike glycoprotein. Moreover, a set of 
molecular mechanics (MM) Poisson-Boltzmann (PB) surface area (SA) calculations on the investigated drugs-
protein systems were performed and the estimated binding free energy of remdesivir and the apo form of Mpro 
system was found to be the best. The interaction results of FDA drugs with the apo form of COVID-19 Mpro and 
spike glycoprotein can play an important role for the treatment of COVID-19. 
  




Corona viruses belong to the family of Coronaviridae, a family of enveloped-single strand 
positive RNA viruses. The Coronaviridae family is divided into four types (α, β, γ and δ) [1]. 
The corona viruses of the alpha and β strains usually infect mammals and humans, while the 
species γ and δ infect birds. This specification was made according to the phylogenetic analysis 
of corona viruses and genome structure [2]. Corona virus SARS-CoV-2 (virus that causes 
COVID-19) is a new corona virus of the genus β [2, 3]. The novel corona virus is highly 
homologous to the known SARS-CoV corona virus that caused an outbreak of severe acute 
respiratory syndrome (SARS) in 2000-2004, however it is not the same virus. There are 
currently no vaccines and/or specific therapeutic drugs that target SARS-CoV-2. Until we had 
specific vaccines or therapeutic drugs targeting SARS-CoV-2, FDA-approved "restructured" 
drugs would be used to treat patients with COVID-19. [4-6]. The protein called angiotensin 
converting enzyme 2 or ACE2 “receptor” is thought to provide the entry point for SARS-CoV-2 
to bind and infect a wide variety of human cells, as like as SARS CoV. 
FDA approved drugs, chloroquine (CQ), hydroxychloroquine (HCQ), remdesivir (RDV) and 
arbidol (USA) appear as promising antivirals to fight COVID-19. In this study molecular 
docking of the FDA approved drugs with COVID-19 Mpro were investigated. The hypothesis 
behind molecular docking studies is to identify the binding affinities of these drugs and identify 
key amino acid residues that play an important role in their mechanism of action. 
In this study the interaction mechanisms of the 7 FDA approved drugs were investigated by 
docking of drugs with COVID-19 Mpro and spike glycoprotein. The docked drugs were 
hydroxychloroquine, remdesivir, arbidol, favipiravir, colchicine, galidesivir and dexamethasone. 
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The results of trials and clinical studies on these drugs were summarized by Mohapatra et al. in 
2020 [7]. 
The spike protein (S protein) of SARS-CoV has very important roles in viral infection and 
pathogenesis [1]. The main protease (MPro) of SARS-CoV-2 is an enzyme essential for virus 
replication through viral proteolytic activity and subsequent generation of infectious virus 
particles. [8]. The SARS-CoV-2 MPro active site has two conformational stages: Apo (closed 
conformation) and holo (open conformation) stages [8]. 
In a study performed by Amin and Abbas [9], the in-silico interactions of chloroquine and 
hydroxychloroquine with the N terminal domain (NTD) of nucleocapsid protein (N protein) 
(NTD-N-protein) of SARS-CoV-2 were investigated and it was reported that these drugs bind 
efficiently to the active sites of the NTD-N-protein and reduce the efficacy. 
In a study conducted by Rachakulla and Rachalulla [10], the in silico docking study was 
performed to reveal the potential bond affinity and binding interactions of dexamethasone 
remdesivir, hydroxyquinoline, favipiravir against COVID-19 Mpro. It was found that 
dexamethasone, approved by the FDA for other medical purposes, has a high potential bond 
affinity and binding interactions against the SARS-CoV-2 protease compared to drugs currently 
used for COVID-19 treatment. However, it was noted that further clinical trials were needed to 
recommend as alternative medical treatments for COVID-19 [10]. 
Khan and Htar compared the binding affinities of the remdesivirin and dexamethasone for 
the SARS-COV-2 Mpro to find out the most preventive potential against COVID-19 [11]. 
Dexamethasone was found to bind with a high affinity to the same sites of the SAR-COV-2 Mpro 
better than remdesivir, due to having more hydrogen bonds than remdesivir antiviral drug. 
In the study of Blaising et al., the physicochemical properties, pharmacokinetics, toxicity 
and molecular mechanisms of the arbidol drug, were investigated and predicted its possibility 
and suitability of a broad spectrum antiviral. It was thought that the interactions of arbidol with 
membranes and aromatic amino acids in proteins could be at the center of broad spectrum 
antiviral activity [12]. 
  In this study, conformational analyzes of hydroxychloroquine, dexamethasone, favipiravir, 
arbidol, galidesivir, colchicine, remdesivir molecules were carried out to examine the 
energically possible conformers and to reveal their stability. In order to understand the 
biological activity and mechanism of these molecules against COVID-19 Mpro, molecular 
docking study was carried out with apo and holo forms of COVID-19 Mpro and spike 
glycoprotein. The drugs were sorted on the basis of binding strength. 
 
METHODS AND CALCULATIONS 
 
Conformation analysis and optimized geometries of the seven molecules examined 
(hydroxychloroquine, dexamethasone, favipiravir, arbidol, galidesivir, colchicine, remdesivir). 
The analysis was performed using the Spartan06 program [13] using the AM1 semiempirical 
quantum mechanical method [14]. 
The potential binding sites on the surface of the receptors were determined using the 
Cavityplus program [15]. Molecular docking studies were performed on the identified active 
sites [16], using AutoDock-Vina software. The binding free energies of the most stable ligand-
protein systems that determined by molecular docking analysis, were calculated by the programs 
developed by Wang [17] and the ACFIS 2.0 web server [18-21]. 
 
RESULTS AND DISCUSSION 
 
The spike protein, the main antigenic component responsible for inducing host immune 
responses, neutralizing antibodies, and protective immunity against virus infection, is a 
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structural protein of SARS-CoV. Therefore, spike protein is chosen as the target for the presence 
of corona virus vaccine and development of anti-viral drugs [22]. The Mpro is a vital role in 
polyprotein processing and virus maturation, for this reason COVID-19 Mpro is an attractive 
drug target for antiviral drug design toward COVID-19 treatment. Cavities of apo and holo 
forms of COVID-19 Mpro and spike glycoprotein of SARSCoV-2 receptors were determined 
using the Cavityplus program [15]. Among these cavities, the cavities with the highest 
probability of binding molecules were determined according to drug score and Pred Max pKd 
value. Respectively three and one druggable cavities were determined according to drug score 
value in apo form of COVID-19 Mpro and spike glycoprotein, and also one cavity was 
determined according to Pred Max pKd value in holo form of COVID-19 M
pro. Using the 
AutoDock Vina program [16], the molecules were docked to the active sites which are 
druggable cavities. The crystal structures of spike glycoprotein (PDB ID: 6VXX), apo form of 
COVID-19 Mpro (PDB ID: 6M03) and holo form of COVID-19 Mpro(PDB ID: 6LU7) were 
obtained from the protein database [23-25]. The docking for molecules was adapted by 
removing the water molecule from the receptors and adding polar hydrogens. The active sites of 
the apo and holo forms of the COVID-19 Mpro and the spike glycoprotein of SARSCoV-2 were 
defined in the grid size of 40 Å × 40 Å × 40 Å. 
In Table 1, the binding sites, binding energies of apo and holo forms COVID-19 Mpro and 
spike glycoprotein protein with drugs are given. Figures 1-7 presents the interactions between 
target proteins and drugs. 
The interactions between the arbidol molecule and the apo form of COVID-19 Mpro are as 
follows (see Figure 1): 3.98 Å long alkyl interaction with the Val104 amino acid; 2.59 Å long 
hydrogen bond interaction between arbidol and the Gln110 amino acid; 3.33 Å long hydrogen 
bond interaction with the Asn151 amino acid; 3.94 Å long pi-sigma interaction with the Phe294 
amino acid; 3.99 Å long pi-sigma interaction with the  Val303 amino acid; 5.03 Å long pi-sulfur 
interaction with the  Phe305 amino acid. Our results are in accord with previous findings. 
Recently, Sing and Flores [26] investigated the interactions between apo form of Mpro (PDB ID: 
6M03) and some molecules that could be used as therapeutics against COVID-19 disease 
including ramipril benzyl ester, propafenone dimer, lariciresinol, citrusinol, segatalin, 
cinobufagin and vitisnol C. Their results were in accord with our findings [26]. The molecular 
docking analysis performed by Sing and Flores [26] revealed that ramipril benzyl ester interacts 
with Asn151, Phe294 and Val 303 amino acid residues of the target protein 6M03. Moreover the 
results showed that, propafenone dimer interacts with Gln110, Phe294, and Phe305, citrusinol 
molecule interacts with Asn151 and Gln110 residues. These results are in accord with our 
findings. Our docking simulations showed that arbitol molecule is involved in interaction with 
Gln110, Asn151, Phe294, Val303 and Phe305 amino acid residues of Mpro target protein. The 
docking outcomes suggest that arbitol binds to the same amino acid residues as the other 
molecules [26], which are known to be effective against COVID-19. Arbitol showed better 
binding affinity for the apo form of Mpro (-6.5 kcal/mol) then the holo form (-6.0 kcal/mol). 
Colchicine showed better binding affinity for the SARS-COV2-spike glycoprotein (-6.9 
kcal/mol) then the apo form of Mpro (-6.8 kcal/mol) (see Figure 2). Colchicine interacted with 
Arg466, Asp467 and Ile468 residues of the spike glycoprotein. In the study on the molecular 
interaction docking between synthetic peptides and SARS-CoV-2 spike glycoprotein [27] the 
presence of an interaction between Mo-CBP3-PepII peptide and through Arg466 residue of 
spike glycoprotein was shown. TheArg466 is the same amino acid residue of spike glycoprotein 
that the colchicine molecule interacts. 
As a result of molecular docking analysis of dexamethasone with the apo form of COVID-
19 Mpro, the following interactions are yielded (see Figure 3): 5.01 Å long pi-alkyl interaction 
with Phe8 residue; 3.83 Å long Alkyl interaction with Arg298 residue; 4.71 Å long alkyl 
interaction with Val303 residue and 4.57 and 5.47 Å long pi-alkyl interactions with Phe305 
residue. Comparison of our results with those of ramipril benzyl ester coupled with 6M03 [26] 
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showed that the amino acids with which the dexamethasone molecule interacted were the same 
as the ramipril benzyl ester molecule, indicating that the binding active site in the apo form was 
the same. The dexamethasone showed a better binding affinity for the apo form of Mpro (-8.6 
kcal/mol) than the holo form (-7.8 kcal/mol) and the spike glycoprotein (-7.4 kcal/mol). 
 
Table 1. The binding affinity values of the title compounds predicted by Autodock Vina. 
 
Drugs Apo Form (6M03) Holo Form (6LU7) Spike (6VXX) 





















































































Binding affinity (-6.4 kcal/mol) (-6.3 kcal/mol) (-6.2 kcal/mol) (-6.2 kcal/mol) (-7.1 kcal/mol) 

















































Binding affinity (-6.8 kcal/mol) (-6.2 kcal/mol) (-7.7 kcal/mol) (-6.6 kcal/mol) (-5.7 kcal/mol) 
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Figure 1. 2-D molecular docked structure of arbidol with the apo form of COVID-19 Mpro. 
Doted lines present the interactions of arbidol with apo form (cavity3; binding affinity, 
-6.5 kcal/mol). 
 
Figure 2. 2-D molecular docked structure of colchicine with Spike glycoprotein. Doted lines 
present the interactions of colchicines with spike glycoprotein (cavity5; binding 
affinity, -6.9 kcal/mol). 
 
Figure 3. 2-D molecular docked structure of dexamethasone with the apo form of COVID-19 
Mpro. Doted lines present the interactions of dexamethasone with apo form (cavity3; 
binding affinity, -8.6 kcal/mol). 
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Figure 4. 2-D Molecular docked structure of favipiravir with the holo form of COVID-19 Mpro. 





Figure 5. 2-D Molecular docked structure of galidesivir with Spike glycoprotein. Doted lines 
present the interactions of galidesivir with spike glycoprotein (cavity5; binding 
affinity, -7.1 kcal/mol). 
 
 
Figure 6. 2-D molecular docked structure of hydroxychloroquine with Spike glycoprotein. 
Doted lines present the interactions of hydroxychloroquine with spike glycoprotein 
(cavity5; binding affinity, -6.4 kcal/mol). 
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Figure 7. 2-D molecular docked structure of remdesivir with the apo form of COVID-19 Mpro. 
Doted lines show the interactions of remdesivir with Mpro. (cavity3; binding affinity     
-7.7 kcal/mol). 
 
The favipiravir showed a better binding affinity for the holo form of COVID-19 Mpro (-5.7 
kcal/mol) than the apo form (-5.3 kcal/mol) and the spike glycoprotein(-5.1 kcal/mol). The 
favipiravir interacts with the holo form of COVID-19 Mpro through H-bonds (see Figure 4). Å 
long hydrogen bond interaction between the molecule and the Asn151 amino acid; 2.08 Å long 
hydrogen bond interaction with Thr292 amino acid; 2.26 Å long hydrogen bond interaction with 
Asp295 amino acid are revealed. In the molecular docking analysis of some antiviral 
compounds against holo form of COVID-19 Mpro (6LU7), it has been revealed that the antiviral 
compounds {niclosamide (C13H8Cl2N2O4), +(-)epicatechin (C15H14O6), diterpene (C21H28O7), 
niclosamide (C13H8Cl2N2O4)}interact with the Asn151, Thr292 and Asp295 amino acid residues 
of the holo form of Mpro (6LU7), which are the same amino acid residues that favipiravir 
interacts [28]. 
The binding affinity of the galidesivir to the spike glycoprotein (-7.1 kcal/mol) is better than 
the binding affinity to the apo (-6.4 kcal/mol) and holo (-6.2 kcal/mol) forms of COVID-19 
Mpro. The molecular docking study of galidesivir with spike resulted in H-bonding interactions 
between the drug and spike glycoprotein residues as follows (see Figure 5): 3.09 Å long 
hydrogen bond interaction with the Asp88 amino acid; 2.49 Å long hydrogen bond and 3.59 Å 
long carbon hydrogen bond interactions with the  Asn196 amino acid; 2.65 Å long hydrogen 
bond interaction with the  Asn234 amino acid; 2.54 and 2.21 Å long hydrogen bond interaction 
with the Ile235 amino acid and4.94Å long pi-cation interaction with the Lys462 amino acid. In a 
recent study molecular simulation analyses of SARS-CoV-2 spike protein with 
phytoconstituents of Withania somnifera Dunal Habit (including Viscosalactone B) which are 
known to have various bioactivities, were performed [29] and is shown that viscosalactone B 
(C28H40O7) molecule interacts with Asp88, Asn196, Asn234 and Ile235 residues of the spike 
glycoprotein. These are the same amino acid residues of the spike glycoprotein that galidesivir 
interacts with. The results indicate that the binding active site within spike glycoprotein for 
viscosalactone B molecule is the same as the galidesivir molecule we studied. 
The interactions of the hydroxychloroquine molecule with spike glycoprotein are as follows 
(see Figure 6): 1.45 Å long unfavorable donor-donor interaction between the Thr108 amino acid 
of the target protein and hydroxychloroquine; 5.33 Å long and 5.09 Å long pi-alkyl interactions 
between the Lys462 residue and the drug. The hydroxychloroquine shows better binding affinity 
for the spike glycoprotein (-6.4 kcal/mol) than those for the apo (-5.9 kcal/mol) and holo (-5.2 
kcal/mol) forms of COVID-19 Mpro. 
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The molecular docking studies of the remdesivir molecule with Apo form of COVID-19 
Mpro yielded the following interactions between remdesivir molecule and the aminoacid residues 
of target protein (see Figure 7): 2.92 Å long hydrogen bond interaction with the Gln110 residue; 
2.83 and 3.07 Å long hydrogen bond interactions with the Thr111 amino acid residue; 2.90 Å 
long unfavorable acceptor-acceptor interaction between the Asn151 amino acid residue; 4.85 Å 
long alkyl interaction between the Pro252 residue; 4.70 Å long Pi-Alkyl interaction and 2.52 Å 
long hydrogen bond interaction with the Phe294 residue; 2.20 Å long hydrogen bond interaction 
with the Asp295 residue; 4.19 Å long Alkyl interaction with the Val297 residue; 4.86 Å long 
unfavorable positive-positive interaction and 2.77 Å long; hydrogen bond interaction with the 
Arg298 residue; 4.47 Å long pi-alkyl interaction with the Val303 amino acid residue. The 
remdesivir shows better binding affinity for the apo form of Mpro, (-7.7 kcal/mol) than for the 
holo (-6.6 kcal/mol) form and spike glycoprotein (-5.7 kcal/mol). 
Molecular mechanical energies combined with Poisson-Boltzmann or generalized Born and 
surface area continuous solving (MM/PBSA and MM/GBSA) methods are approaches used to 
estimate the free energy of binding small ligands to biological macromolecules. Typically they 
are based on molecular dynamics simulations of the receptor-ligand complex. These approaches 
are used to estimate the free energy of binding small ligands to biological macromolecules [17-
21, 30]. Typically they are based on molecular dynamics simulations of the receptor-ligand 
complex.  
Due to the importance of MM/PBSA and MM/GBSA approaches, the binding free energies 
were calculated using two different programs, 1) a program developed by Wang [17], which is 
based on MM/PB(GB)SA approach and 2) ACFIS (ACFIS 2.0) a computer-aided fragment-
based drug discovery (FBDD) web server [18-21]. 
The predicted binding free energy of the arbidol-Apo form, dexamethasone-Apo form and 
remdesivir-Apo form were -17.71, -31.89 and -3.87 kcal/mol, respectively by using the 
MM/PB(GB)SA approaches with the GAFF2 and ff14SB force field combination and the GB6 
procedure [17]. We could not perform the calculations for all studied molecules due to the 
insufficiency of the program, which was designed for limited size receptors. 
Secondly the free energy of the binding of the investigated molecules to COVID-19 Mpro 
and spike glycoprotein (ΔG) were calculated both with MM/PBSA {ΔG(PB)} and MM/GBSA 
{ΔG(GB)} methods using ACFIS 2.0 web server [18-21] and the estimated binding free 
energies { ΔG(PB) and  ΔG(GB)}of the drug-protein system are as follows: 
  Arbidol-Apo form: ΔG(PB) = -12.78 kcal/mol ; ΔG(GB) = -20.93 kcal/mol 
  Dexamethasone-Apo form: ΔG(PB) = -11.55kcal/mol ; ΔG(GB) = -16.92 kcal/mol 
  Remdesivir-Apo form: ΔG(PB)= -20.61 kcal/mol ; ΔG(GB)=  -30.09 kcal/mol  
  Favipiravir-Holo form:   ΔG(PB)=  -4.79 kcal/mol; ΔG(GB)= -7.82 kcal/mol  
  Colchicine- spike protein: ΔG(PB)= -1.74 kcal/mol ; ΔG(GB)= -14.34 kcal/mol  
  Galidesivir-spike protein:  ΔG(PB)= 6.13 kcal/mol; ΔG(GB)=  8.89  kcal/mol  




We performed an in silico molecular docking simulations on the interaction of 7 FDA approved 
drugs with both apo and holo forms of the Mpro enzyme of SARS-CoV-2. Moreover, the 
interactions of these 7 drug molecules with Spike glycoprotein protein were also investigated. 
The cavityplus program were used to determine the druggable cavities of the both apo and  holo 
forms of the COVID-19 Mpros and the spike glycoprotein of the SARSCoV-2 receptors. By 
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comparing all the compounds that interacted with COVID-19 Mpro based on the binding affinity, 
dexamethasone (-8.6 kcal/mol) followed by remdesivir (-7.7 kcal/mol) and galidesivir (-7.1 
kcal/mol) have a good binding affinity. Moreover, galidesivir has been shown to have the best 
binding affinity for the Spike glycoprotein (-7.1 kcal/mol) among the studied compounds. In 
addition a set of molecular mechanics (MM) Poisson-Boltzmann (PB) surface area (SA) 
calculations on the investigated drugs and apo form of COVID-19 Mpro were also performed. By 
comparing all the compounds that interacted with COVID-19 Mpro based on the binding free 
energy, remdesivir showed the best interaction with the apo form of the Mpro{ΔG(PB): -20.61 
kcal/mol; ΔG(GB): -30.09 kcal/mol}. All interactions between receptors and molecules and 
their binding affinities are explained in detail, these results are thought to be important for the 
treatment of COVID-19. 
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